List view / Grid view
Artificial intelligence is increasingly used to analyse large, multimodal Alzheimer’s datasets and inform target discovery and trial design. A new JPAD special issue highlights how these methods are moving from experimentation towards practical application in drug discovery.
A new US-based company has launched with the aim of tackling one of the most persistent operational challenges in modern drug discovery – the slow and fragmented handling of physical compounds.
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.
Mutant selectivity remains one of drug discovery’s hardest problems. New preclinical research applying quantum chemistry to JAK2V617F illustrates how detailed molecular analysis can inform more selective inhibitor design.
ABB Robotics will present live demonstrations highlighting how artificial intelligence and collaborative robots can deliver faster, more connected laboratory operations.
For those that hoped artificial intelligence would help to deliver drugs that actually work, the hope lives on. Here, Dr Raminderpal Singh reflects on the sobering reality check that 2025 delivered to the industry.
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
Scientists have identified early blood biomarkers for Parkinson’s disease, revealing a narrow window in which the condition could be detected years before symptoms appear.
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
A newly developed AI-driven technique could dramatically speed up the discovery of drugs and advanced materials, enabling scientists to design chemically valid, property-targeted molecules in minutes rather than years.
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
